Seoulin Bioscience Co.,Ltd.

KOSDAQ:A038070 Stock Report

Market Cap: ₩44.0b

Seoulin BioscienceLtd Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Eul-Moon Hwang

Chief executive officer

₩782.0m

Total compensation

CEO salary percentage58.82%
CEO tenureno data
CEO ownership30.2%
Management average tenureno data
Board average tenureno data

Recent management updates

Recent updates

Analysis Article • Nov 26

Solid Earnings May Not Tell The Whole Story For Seoulin BioscienceLtd (KOSDAQ:038070)

Seoulin Bioscience Co.,Ltd.'s ( KOSDAQ:038070 ) robust recent earnings didn't do much to move the stock. We think this...
Analysis Article • Mar 25

Concerns Surrounding Seoulin BioscienceLtd's (KOSDAQ:038070) Performance

The market shrugged off Seoulin Bioscience Co.,Ltd.'s ( KOSDAQ:038070 ) solid earnings report. We think that investors...
Analysis Article • Dec 04

Seoulin Bioscience Co.,Ltd.'s (KOSDAQ:038070) Low P/S No Reason For Excitement

With a price-to-sales (or "P/S") ratio of 0.9x Seoulin Bioscience Co.,Ltd. ( KOSDAQ:038070 ) may be sending very...
Analysis Article • May 03

Seoulin Bioscience Co.,Ltd. (KOSDAQ:038070) Is An Attractive Dividend Stock - Here's Why

Dividend paying stocks like Seoulin Bioscience Co.,Ltd. ( KOSDAQ:038070 ) tend to be popular with investors, and for...
Analysis Article • Mar 13

Should Weakness in Seoulin Bioscience Co.,Ltd.'s (KOSDAQ:038070) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Seoulin BioscienceLtd (KOSDAQ:038070) has had a rough three months with its share price down 8.8%. However, the...
Analysis Article • Feb 15

Introducing Seoulin BioscienceLtd (KOSDAQ:038070), A Stock That Climbed 54% In The Last Year

Seoulin Bioscience Co.,Ltd. ( KOSDAQ:038070 ) shareholders might be concerned after seeing the share price drop 11% in...
Analysis Article • Jan 20

Is Seoulin Bioscience Co.,Ltd. (KOSDAQ:038070) A Great Dividend Stock?

Today we'll take a closer look at Seoulin Bioscience Co.,Ltd. ( KOSDAQ:038070 ) from a dividend investor's perspective...
Analysis Article • Dec 25

Three Days Left Until Seoulin Bioscience Co.,Ltd. (KOSDAQ:038070) Trades Ex-Dividend

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...
Analysis Article • Dec 06

Is Seoulin Bioscience Co.,Ltd.'s (KOSDAQ:038070) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Seoulin BioscienceLtd (KOSDAQ:038070) has had a great run on the share market with its stock up by a significant 10...

CEO Compensation Analysis

How has Eul-Moon Hwang's remuneration changed compared to Seoulin BioscienceLtd's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

₩518m

Dec 31 2025n/an/a

₩732m

Sep 30 2025n/an/a

₩2b

Jun 30 2025n/an/a

₩2b

Mar 31 2025n/an/a

₩3b

Dec 31 2024₩782m₩460m

₩3b

Sep 30 2024n/an/a

-₩662m

Jun 30 2024n/an/a

-₩591m

Mar 31 2024n/an/a

-₩1b

Dec 31 2023₩780m₩460m

-₩118m

Compensation vs Market: Eul-Moon's total compensation ($USD512.99K) is about average for companies of similar size in the KR market ($USD507.57K).

Compensation vs Earnings: Eul-Moon's compensation has been consistent with company performance over the past year.

CEO

Eul-Moon Hwang

no data
Tenure
₩782,000,000
Compensation

Eul-Moon Hwang is Chief Executive Officer of Seoulin Bioscience Co.,Ltd.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/10 14:19
End of Day Share Price 2026/06/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Seoulin Bioscience Co.,Ltd. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sung Hwan ChoiKyobo Securities Co., Ltd
Ju-Hong ChoeLS Securities Co., Ltd.
Seung KimSK Securities Co., Ltd.